Holder evidence
16
SEC ownership of Clovis Oncology, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001466301.
Lead holder
Gillian Ivers-Read
13D/G signal
—
Latest evidence
01 Nov 2022
- CIK
- 0001466301
- Location
- Boulder, CO
- SEC evidence mix
- 3/4/5
- Lead holder
- Gillian Ivers-Read
- Latest evidence date
- 01 Nov 2022
Issuer identity
2 facts
Ownership snapshot
3 facts
Ownership snapshot
Top shareholders of Clovis Oncology, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
Gillian Ivers-Read
13D/G signal
—
Evidence rows
16
Latest as of
01 Nov 2022
3/4/5
Highest disclosed value: $288,591
Showing 1-8 of 16 holder rows.
Rank 1 holder
Gillian Ivers-Read
3/4/5
- Ownership
- —
- Position
- $288.6K
Rank 2 holder
Lindsey Rolfe
3/4/5
- Ownership
- —
- Position
- $111.7K
Rank 3 holder
Daniel W. Muehl
3/4/5
- Ownership
- —
- Position
- $103K
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Gillian Ivers-Read |
3/4/5
Executive Vice President of Technical Operations and Chief Regulatory Officer
|
—
mixed-class rows
|
$288,591
316,737 shares
mixed-class rows
|
— | 01 Nov 2022 |
| Lindsey Rolfe |
3/4/5
Officer
|
—
mixed-class rows
|
$111,747
136,816 shares
mixed-class rows
|
— | 01 Nov 2022 |
| Daniel W. Muehl |
3/4/5
Executive Vice President and Chief Financial Officer
|
—
mixed-class rows
|
$103,037
127,955 shares
mixed-class rows
|
— | 01 Nov 2022 |
| Paul Edward Gross |
3/4/5
Executive Vice President and General Counsel
|
—
mixed-class rows
|
$96,649
121,455 shares
mixed-class rows
|
— | 01 Nov 2022 |
| Thomas C. Harding |
3/4/5
Senior Vice President and Chief Scientific Officer
|
—
mixed-class rows
|
$22,890
33,258 shares
mixed-class rows
|
— | 01 Nov 2022 |
| Ronit Simantov |
3/4/5
Director
|
—
class O/S missing
|
—
83,212 shares
|
— | 12 Jul 2021 |
| Patrick J. Mahaffy |
3/4/5
President and Chief Executive Officer, Director
|
—
class O/S missing
|
—
80,000 shares
|
— | 01 Mar 2022 |
| BLAIR JAMES C |
3/4/5
Director
|
—
class O/S missing
|
—
42,223 shares
|
— | 10 Jun 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 01 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to Clovis Oncology, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Lead holder
Gillian Ivers-Read
Net 12M change
$0
Latest report
01 Nov 2022
Recent insider transactions for Clovis Oncology, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* indicates a reported price that failed the local validity check.